Effects of High Potency Cannabis Products on Mental Health and Psychosocial Functioning

高效大麻产品对心理健康和心理社会功能的影响

• 批准号: 10618709
• 负责人: Christian J Hopfer
• 金额: $ 70.71万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-05-15 至 2028-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10618709
• 关键词: Accounting; Acute; Adolescence; Affect; Anxiety; Blood; Cannabinoids; Cannabis; Cannabis policy; Cannabis retail; Consumption; Controlled Study; Data; Dose; Drug usage; Education; Exhibits; Family; Flowers; Frequencies; Functional disorder; Genetic; Impulsivity; Individual; Individual Differences; Intoxication; Legal; Link; Literature; Marketing; Measures; Mental Depression; Mental Health; Methods; Neurocognitive; Outcome; Participant; Persons; Plasma; Prevalence; Psyche structure; Psychopathology; Reporting; Research; Risk; Risk Factors; Sales; Sampling; Symptoms; THC exposure; Testing; Time; Titrations; Twin Multiple Birth; Twin Studies; United States; Whole Blood; Work; design; low socioeconomic status; marijuana legalization; marijuana use; psychosocial; public health relevance; response; substance use

The rapidly changing landscape of cannabis policy in the United States is well known, but often overlooked is that legalization has made high-potency products more available. State-regulated cannabis markets offer access to cannabis products, such as concentrates with THC potencies (70-90%) that far exceed cannabis that has been sold on the black market over the last 20 years (4-12% THC potency). State reporting suggests that concentrates are commonly used and quickly rising in popularity, with increases in 2014-2019 sales (409%) far outpacing that of flower (80% increase) and edibles (234% increase). Recent data indicate that concentrate users exhibit higher plasma THC levels than flower users and a large body of research has demonstrated dose-response relationships between increasing cannabis consumption and poor mental health outcomes. Given the increasing prevalence of concentrate use, it is imperative to clearly understand how these increasingly popular, high-potency cannabis products affect mental health and psychosocial functioning. This project leverages an ongoing, longitudinal twin study, with participants assessed approximately every 5 years since adolescence. Thus, this project is a unique opportunity to rigorously test critical hypotheses about how high-potency concentrates affect psychopathology and psychosocial functioning. The Aims of this research are: Aim 1: Examine how the use of different cannabis products relates to cannabinoid exposure (e.g., THC). We will test whether the use of high-potency cannabis concentrates, compared to flower products, is associated with elevated cannabinoid exposure. We hypothesize that associations will not be explained by familial confounds (via co-twin comparisons) and individual differences (via repeated assessments). Alternatively, it is possible that concentrate users titrate to reach the same effect as flower users. Aim 2: Examine how the use of different cannabis products relates to mental health and psychosocial functioning. It is plausible that individuals vary in their propensity to use high-potency concentrates. Thus, we will examine how use of high-potency concentrates relate to mental health while accounting for familial and individual confounds, like genetics and prior substance use. We hypothesize that twins who uses more high- potency concentrates will tend to have greater levels of depression, anxiety, and impulsivity and psychosocial dysfunction compared to their co-twins who use flower or who use high-potency concentrates less frequently. Aim 3: Test whether different levels of cannabinoid exposure are associated with mental health and psychosocial outcomes. We will test how different levels of cannabinoid exposure (i.e., THC-COOH concentrations in whole blood) associate with depression, anxiety, and impulsivity as well as psychosocial functioning. That is, we will directly test the hypothesis that cannabinoid exposure is associated with mental health and psychosocial functioning. We hypothesize that higher levels of cannabinoid exposure will be associated with worse symptoms of mental health and psychosocial functioning.

美国大麻政策的迅速变化是众所周知的，但经常被忽视的是， 这种合法化使高效力产品更容易获得。国家管制的大麻市场提供 获得大麻产品，如THC效力（70-90%）远远超过大麻的浓缩物， 在过去的20年里，它一直在黑市上出售（4-12% THC效力）。国家报告表明， 浓缩物是常用的，并迅速普及，2014-2019年的销售额增长（409%）远远超过了 超过了花卉（增长80%）和食用品（增长234%）。最近的数据显示， 使用者的血浆THC水平高于鲜花使用者，大量研究表明， 增加大麻消费与不良心理健康结果之间的剂量反应关系。 鉴于浓缩物使用的日益普遍，必须清楚地了解这些 越来越受欢迎的高效力大麻产品影响心理健康和社会心理 功能该项目利用了一项正在进行的纵向双胞胎研究， 从青春期开始大约每5年一次。因此，这个项目是一个独特的机会， 关于高效浓缩物如何影响精神病理学和社会心理功能的关键假设。 本研究的目的是： 目标1：研究不同大麻产品的使用与大麻素暴露的关系（例如， THC）。我们将测试与花卉产品相比，使用高效大麻浓缩物是否 与大麻素暴露量增加有关我们假设，关联不会被解释为 家族性混淆（通过双胞胎比较）和个体差异（通过重复评估）。 或者，浓缩使用者滴定以达到与花使用者相同的效果是可能的。 目标2：研究不同大麻产品的使用与心理健康和社会心理的关系 功能似乎每个人使用高效浓缩物的倾向各不相同。因此我们 将研究使用高效浓缩物与心理健康的关系，同时考虑家庭和 个人混淆，如遗传学和先前的物质使用。我们假设使用高- 集中精力的人往往会有更大程度的抑郁、焦虑、冲动和心理社会问题。 与使用花或使用高效浓缩物频率较低的双胞胎相比，他们的功能障碍。 目标3：测试不同水平的大麻素暴露是否与心理健康相关， 心理社会结果。我们将测试不同水平的大麻素暴露（即，THC-COOH 全血中的浓度）与抑郁、焦虑和冲动以及心理社会 功能也就是说，我们将直接测试大麻素暴露与精神疾病相关的假设。 健康和心理社会功能。我们假设，更高水平的大麻素暴露将 与心理健康和心理社会功能的症状恶化有关。